September 28, 2015

Profounda licenses Impavido from Knight Therapeutics for marketing into the US.  Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused...

September 28, 2015


MONTREAL, Canada, September 25, 2015 – Knight Therapeutics Inc. (TSX: GUD) (“Knight”), through one of its wholly-owned subsidiaries, announced today that it has entered into an exclusive distribution agreement with Profounda Inc. (“Profounda”) to commercialize Impavid...

Please reload

Featured Posts

http://www.clickorlando.com/news/broward-teen-survives-brain-eating-amoeba-was-treated-in-orlando

Patient survives Brain Eating Amoeba

September 12, 2016

1/3
Please reload

Recent Posts
Please reload

Archive
Please reload

Search By Tags
Please reload

© Profounda Pharmaceuticals